FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C. 20549
-------------	------------

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See	STATEMENT OF CHA
Instruction 1(h)	Filed purguant to Sec

ANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Wedell-Wedellsborg Johan					<u>Y-n</u>	Issuer Name and Ticker or Trading Symbol Y-mAbs Therapeutics, Inc. [YMAB] 3. Date of Earliest Transaction (Month/Day/Year)									all app Direc	olicable)		erson(s) to Issuer 10% Owner Other (specify		
(Last)	(Fir	,	Middle)		11/27/2023									below			below)	specify	
C/O Y-MABS THERAPEUTICS, INC. 230 PARK AVENUE, SUITE 3350					4. If <i>i</i>	4. If Amendment, Date of Original Filed (Month/Day/Year)								Indiv ne) X	-/					
(Street) NEW YO	ORK NY	? 1	10169												Form filed by More than One Reporting Person					
(City)	(Sta	ate) (Z	Zip)		l.,	Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.													nded to	
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																				
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Y				rear)	Execution Date,			3. Transaction Code (Instr. 8)		4. Securities Acquired (A) of Disposed Of (D) (Instr. 3, 4 a			and 5) Securi Benefi		ties cially I Following	Form (D) o	n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
								Code	v	Amount	(A) or (D)	Price		Transa	saction(s) r. 3 and 4)			(IIISU. 4)		
Common Stock 11/27/				11/27/20	23				P		62,516	A	\$5.486	19 (1)	4,342,721			I	By WG Biotech ApS ⁽³⁾	
Common Stock 11/28			11/28/20	23				P		30,671	A	\$5.812	.5 ⁽²⁾	4,373,392			I	By WG Biotech ApS ⁽³⁾		
		Tal	ble II	- Derivati (e.g., pu							posed of, convertib)wne	d				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Exec if any	Deemed ution Date, / /th/Day/Year)	on Date, Transaction Code (Instr.				Expi	ate Exer ration I nth/Day		7. Title Amou Secur Under Deriva Secur 3 and	nt of ities lying ative ity (Instr.	Der Sec	Price of rivative curity str. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transactions (Instr. 4)	y	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code V		(A)	(D)	Date Exercisable		Expiration Date	Title	Amount or Number of Shares							

Explanation of Responses:

- 1. This transaction was executed in multiple trades at prices ranging from \$5.38 to \$5.60. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
- 2. This transaction was executed in multiple trades at prices ranging from \$5.51 to \$6.00. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
- 3. Reporting Person is the majority owner of WG Biotech ApS and as such has sole voting and dispositive power with respect to such shares.

/s/ Johan Wedell-Wedellsborg 11/29/2023

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.